Device Trial Radar · NCT07927478
Transcutaneous Auricular Vagal Neuromodulation Therapy (AVNT™) in Chronic Kidney Disease Autonomic Dysfunction
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jan 2028
Study completion Jan 2028
Sponsor
- Lead sponsor
- NYU Langone HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this pilot study is to establish the feasibility of home-based Auricular Vagal Neuromodulation Therapy (AVNT™) in Chronic Kidney Disease (CKD) patients, generate preliminary efficacy data on autonomic function outcomes, and explore whether timing variation influences treatment response.
Conditions
- Chronic Kidney Disease (CKD) Stages G3 to G5
Interventions
Auricular Vagal Neuromodulation Therapy (AVNT™)Device
The device consists of a handheld stimulation unit (\~2 inches) connected to a tragus earpiece electrode (worn like an in-ear headphone, removed after each session). Participants will undergo AVNT™ at home once daily for 60 minutes either in the morning at 7am or in the evening at 7pm at a pulse width of 250 μs, frequency of 20 Hz, and comfortable, patient-titrated intensity based on personalized perceptual thresholds.
Sham-deviceDevice
The device is equipped with a "ramp-down sham mode". In this mode, no electrical stimulation will occur for the remainder of the session and participant intensity adjustments are disabled. Participants will use the sham-device at home once daily for 60 minutes either in the morning at 7am or in the evening at 7pm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Orthostatic Heart Rate ResponseTime frame: Week 0, Week 2
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NYU Langone Health
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.